circle-image

Short

Trend Resistance

Uptrend Above: 23850

Bull Signal Above: 24150
circle-image

Term

Trend Point Acts

Trend Point: 23770

My PCR: 0.57
1370 Range 690

Bear Market Signal

circle-image

View

Trend Suport

Down Below: 23680

Bear Signal Below: 23470
Short Term View Historic Data

Nifty View Tomorrow: Tuesday 29 Sep 2026

Day Close

22780
Day High

23080
Day Low

22762
Day Avg

22874
28 Sep 2026
5 SMA

23152
10 SMA

23212
20 SMA

23483
50 SMA

23963
200 SMA

24400
5 EMA

22964
10 EMA

22994
20 EMA

23122
50 EMA

23362
Tomorrow
Resist 2

23150
Resist 1

22970
Mid Point

22810
Suport 1

22650
Suport 2

22520
52W High

26373
52w Low

22182
52w Down

13.62%
52w Up

2.7%
Panic View
Resist 2

23510
Resist 1

23240
Mid Point

22840
Suport 1

22445
Suport 2

22240
5d High

23489
5d Low

22762
10d High

23592
10d Low

22762
Days High & Low 20d High

24143
20d Low

22762
50d High

24774
50d Low

22762
All Avg

23381
FFTH

23281
FTTL

23039
TTTH

23499
TTTL

23222
High & Low Avg TTFH

23893
TFFL

23433
High Avg

23558
Low Avg

23231
All Avg

23395
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 28 Sep 2026 22780 23080 22762 23152 23212 23483 23963 24400
2 25 Sep 2026 23140 23162 23020 23278 23274 23553 23994 24417
3 24 Sep 2026 23063 23281 23046 23320 23308 23600 24013 24431
4 23 Sep 2026 23446 23466 23349 23361 23345 23658 24033 24446
5 22 Sep 2026 23329 23489 23285 23315 23364 23702 24045 24459
Nifty Historic Data And Moving Avg

Go Back

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pha...

Posted: 03 Nov 2024

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Since our inception in 2006 with a small base, we have grown strength to strength and for last more than 15 years, we are catering to top Indian pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. We have license to manufacture products through two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP and other major registrations. With the support of our world class manufacturing facilities and a reliable supply value chain, we are continuously thriving to maintain highly efficient operations. The foundation of our Company is our in-house research and development (R&D). which helps to focus on to build an increasingly complex product portfolio and attract and retain customers. We proudly possess a strong team of 1000+ employees. As a responsible corporate entity, we are been continuously endeavouring to comply with Environmental, Social & Governance compliance requirements covering the aspects of Legal compliance, ethics & business conduct, quality & patient safety, human rights, labour and employment, health safety and well-being of employees, sustainability & environmental responsibility, quality management system. Our business includes CDMO business providing research, product development and manufacturing services. We were third fastest growing CDMO in terms of Operating Income over the period Fiscal 2019 to Fiscal 2023 and positioned our Company to benefit from the growth in the CDMO market by developing strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2023 have been a part of our customer base. Our Capabilities World class manufacturing facilities in Baddi, Himachal Pradesh and Our manufacturing facilities have good manufacturing practices certifications in conformity with the format recommended by WHO-GMP, EU-GMP and many other international authorities. Strong R&D focus to build an increasingly complex product portfolio and attract and retain customers Our CDMO product portfolio spans across both acute and chronic therapeutic areas Leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market Well established relationships with our marquee CDMO customer base Our strength in CDMO sphere includes: Our comprehensive CDMO formulation capabilities allow us to offer our customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. We manufacture products that are in all the top ten therapeutic areas by sales in the Indian formulation market in Fiscal 2023 as identified by CRISIL Research. We manufacture products across some of the key therapeutic areas. Our operational track record in successful delivery of products, R&D, quality and technical standards and productivity Strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Our R&D laboratory is equipped with the entire suite of necessary equipment for the development of solid oral and liquid dosage forms Domestic Branded Generics Our Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under our own brand names through online and offline channels. Our branded generic products are generic medicines for which the patents have expired, that are sold directly to our distributors, stockists & retailers. We sell our domestic branded generic products through our pan-Indian network of distributors, stockists and pharmacies. Our generic drug products are also available online through various e-commerce pharmacy sites. We have developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.